This company has been acquired
AERI Stock Overview
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aerie Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.25 |
| 52 Week High | US$15.37 |
| 52 Week Low | US$4.81 |
| Beta | -0.062 |
| 1 Month Change | 0.26% |
| 3 Month Change | 0.59% |
| 1 Year Change | 57.22% |
| 3 Year Change | -17.66% |
| 5 Year Change | -74.98% |
| Change since IPO | 43.73% |
Recent News & Updates
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13Shareholder Returns
| AERI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.1% | -2.2% | -3.7% |
| 1Y | 57.2% | 11.6% | 20.5% |
Return vs Industry: AERI exceeded the US Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: AERI exceeded the US Market which returned -21.7% over the past year.
Price Volatility
| AERI volatility | |
|---|---|
| AERI Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AERI's share price has been volatile over the past 3 months.
Volatility Over Time: AERI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.
Aerie Pharmaceuticals, Inc. Fundamentals Summary
| AERI fundamental statistics | |
|---|---|
| Market cap | US$753.62m |
| Earnings (TTM) | -US$36.55m |
| Revenue (TTM) | US$213.94m |
3.5x
P/S Ratio-20.6x
P/E RatioIs AERI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AERI income statement (TTM) | |
|---|---|
| Revenue | US$213.94m |
| Cost of Revenue | US$23.52m |
| Gross Profit | US$190.42m |
| Other Expenses | US$226.98m |
| Earnings | -US$36.55m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 89.01% |
| Net Profit Margin | -17.09% |
| Debt/Equity Ratio | -190.6% |
How did AERI perform over the long term?
See historical performance and comparison